Jin Medical International Ltd. — Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, furnished on September 24, 2026, reports the closing of a business acquisition by Jin Medical International Ltd., a Cayman Islands exempted company. The report covers September 2026 and is filed by a foreign private issuer that files annual reports on Form 20-F.
Transaction and Key Financial Metrics
- Through Erhua Medical Technology (Changzhou) Co., Ltd., the Company obtained contractual control over Huaxia Qiying (Beijing) Technology Co., Ltd. through variable interest entity contractual arrangements.
- The aggregate purchase price was US$159.4 million, consisting of share consideration and non-share consideration, including specified investment assets, debt, and equity interests.
- The Company issued 71,282,488 Class A ordinary shares as acquisition consideration.
- The Company separately issued 8,479,560 Class A ordinary shares to Veltrion Haskel Holdings Limited and its approved designee as financial advisory compensation.
- Immediately after closing, the Company had 158,194,533 ordinary shares outstanding, comprising 153,425,476 Class A shares and 4,769,057 Class B shares.
- The filing does not provide revenue, net income, cash flow, margins, debt, cash balances, or liquidity metrics for the reporting period.
Material Changes Versus the Prior Comparable Period
The filing does not present comparative operating or financial results. The principal material change is the completion of the acquisition and the resulting issuance of 79,762,048 Class A ordinary shares, representing substantial equity dilution relative to the post-closing share count.
Outlook, Risks, Contingencies, and Unusual Items
- The transfer of Changzhou Zhongjin Medical’s 80% equity interest in Zhongjin Kangma Information Technology (Jiangsu) Co., Ltd. was not completed at closing.
- The parties are required to use commercially reasonable efforts to complete that transfer by September 30, 2026, or, if delayed, no later than October 31, 2026.
- If the transfer is not completed by October 31, 2026, the Company will issue 622,123 Class A ordinary shares as substitute consideration. Those shares would replace, rather than add to, the Kangma Equity component of the purchase price.
- The transaction shares were issued without registration under the Securities Act pursuant to available exemptions and constitute restricted securities subject to transfer restrictions.
- The transaction and related shares may affect ownership, voting power, dilution, integration, and the Company’s future financial results; the filing does not provide detailed operating forecasts or guidance.
- The Form 6-K is incorporated by reference into the Company’s outstanding Form F-3 registration statement, subject to subsequent filings.
Investor Verification Checklist
- Verify the final transfer status and valuation of the Kangma Equity and whether the 622,123-share substitute consideration was triggered.
- Review the Acquisition Agreement and VIE Agreements for the scope of contractual control, economic rights, and termination or enforcement provisions.
- Assess the effect of the 71,282,488 acquisition shares and 8,479,560 advisory shares on dilution, voting control, and per-share value.
- Confirm the composition and fair value of the non-share consideration included in the US$159.4 million purchase price.
- Review subsequent Form 6-K and annual filings for acquired business revenue, profitability, cash flow, debt, liquidity, integration costs, and related-party or regulatory risks.